Combination treatment of RAD001 and BEZ235 exhibits synergistic antitumor activity via down-regulation of p-4E-BP1/Mcl-1 in small cell lung cancer

Bo Hong, Huogang Wang, Ke Deng, Wei Wang, Haiming Dai, Vivian Wai Yan Lui, Wenchu Lin

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Small cell lung cancer (SCLC) is a highly malignant cancer with few targeted therapies. In the study, by mining the Cancer Cell Line Encyclopedia (CCLE) database, we found that PI3K/AKT/mTOR pathway was aberrant in 92% of SCLC cell lines. Moreover, we found that the phosphorylation level of 4E-BP1 was significantly correlated with SCLC sensitivity to RAD001 (mTOR inhibitor) and BEZ235 (PI3K/ mTOR dual inhibitor). Combination of RAD001 and BEZ235 synergistically inhibited the growth of SCLC cells, which was accompanied by enhanced induction of cell cycle arrest and apoptosis. Such a combination dramatically inhibited the activation of AKT, and strongly reduced the phosphorylation of 4E-BP1 and its downstream target Mcl-1. Knock-down of Mcl-1 enhanced the growth inhibition of SCLC cells induced by RAD001 and BEZ235 co-treatment, whereas over-expression of Mcl-1 reduced the growth inhibitory effect. Furthermore, in vivo study demonstrated that the combination treatment suppressed tumor growth more effectively than RAD001 or BEZ235 treatment alone. In summary, our study suggests that combination of BEZ235 and RAD001 may be an effective regimen for SCLC treatment, and p-4E-BP1 may serve as a predictive biomarker for SCLC response to mTOR inhibitor.

Original languageEnglish (US)
Pages (from-to)106486-106498
Number of pages13
JournalOncotarget
Volume8
Issue number63
DOIs
StatePublished - 2017
Externally publishedYes

Keywords

  • BEZ235
  • P-4E-BP1/Mcl-1
  • PI3K/AKT/mTOR
  • RAD001
  • Small cell lung cancer

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Combination treatment of RAD001 and BEZ235 exhibits synergistic antitumor activity via down-regulation of p-4E-BP1/Mcl-1 in small cell lung cancer'. Together they form a unique fingerprint.

Cite this